Clinical Trial Finder

Inclusion Criteria for Part 1, 1bis, 2, 3 and 3bis:

• - Male between 18-55 years of age (extremes included), on the date of signing the informed consent form (ICF).

• - A body mass index (BMI) between 18-30 kg/m2, inclusive.

• - Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and fasting clinical laboratory safety tests available at screening and prior to randomization.

Hemoglobin must not be below the lower limit of normal range. Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be no greater than 1.5x upper limit of normal range (ULN). Other clinical laboratory safety test results must be within the reference ranges, or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator. This list only contains the key inclusion criteria for the healthy volunteers part of the study. Inclusion criteria for Part 4:

• - Male or female between 18-65 years of age (extremes included), on the date of signing the ICF.

• - Diagnosed with plaque psoriasis ≥6 months.

• - Screening Psoriasis Area and Severity Index (PASI) ≥12 (moderate to severe) and affected body surface area (BSA) ≥10%.

• - A body mass index (BMI) between 18-35 kg/m2, inclusive.

This list only contains the key inclusion criteria for Part 4 of the study. Exclusion Criteria for Part 1, 1bis, 2, 3 and 3bis:

• - Known hypersensitivity to the Investigational Medicinal Product (IMP) ingredients or history of a significant allergic reaction to IMP ingredients as determined by the investigator.

• - Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus or history of hepatitis from any cause with the exception of hepatitis A that was resolved at least 3 months prior to first dosing of the IMP.

• - History of or a current immunosuppressive condition (e.g. human immunodeficiency virus [HIV] infection).

This list only contains the key exclusion criteria for the healthy volunteers part of the study. Exclusion criteria for Part 4:

• - Subject has evidence of skin conditions other than psoriasis (e.g., eczema) at the time of screening or baseline visit that would interfere with the evaluation of psoriasis.

• - Subject is unable to discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA) from signing of the ICF up to the end of the study.

This list only contains the key inclusion criteria for Part 4 of the study.

Arms

Experimental: GLPG3970 SAD

Single doses of GLPG3970 at up to 6 dose levels in ascending order

Placebo Comparator: Placebo SAD

Single doses of placebo

Experimental: GLPG3970 MAD

Multiple doses of GLPG3970 at up to 4 dose levels in ascending order, daily for 14 days

Placebo Comparator: Placebo MAD

Multiple doses of placebo

Experimental: GLPG3970 FE-rBA

Single dose of GLPG3970 in fed and fasted state

Experimental: GLPG3970 FE

Single dose of GLPG3970 in fed and fasted state

Experimental: GLPG3970 in psoriasis subjects

Experimental: Placebo in psoriasis subjects

Interventions

Drug: - GLPG3970 oral solution

GLPG3970 for oral administration

Drug: - Placebo oral solution

Placebo for oral administration

Drug: - GLPG3970 capsule

GLPG3970 for oral administration